Veeva Systems Inc. (VEEV / 0LO3.L)

Deep Dive Research Report

April 2026

Section 1: What the Company Does

Veeva Systems makes cloud software for the life sciences industry. Its customers are pharmaceutical companies, biotechs, and medical device makers - the organizations that discover, develop, and sell drugs and therapies. Veeva builds the software those organizations use to run their clinical trials, manage regulatory filings, track the safety of their drugs once approved, control the quality of their manufacturing, and manage the armies of sales representatives who promote those drugs to doctors.

The company does not make drugs. It does not run clinical trials. It provides the software infrastructure that makes those activities possible and compliant. Think of it as the operating system layer for the life sciences industry - invisible to patients, essential to the companies serving them.

The Founding Story

Peter Gassner spent four years as Senior Vice President of Technology at Salesforce in the mid-2000s. He watched the first wave of cloud software sweep through horizontal enterprise categories - CRM, HR, finance - and noticed something: the playbook worked brilliantly for generic workflows, but it broke down the moment a regulated industry needed it. Pharmaceutical companies didn't just need a CRM; they needed one that could handle restricted data about healthcare providers, validate to FDA standards, support global compliance requirements across 65+ countries, and integrate with the specialized workflows that only existed in drug development.

Salesforce built for the broadest possible customer. Gassner saw that building deep for one industry - life sciences - was a different and potentially more durable business. He left Salesforce in 2007, co-founded Veeva Systems with Matt Wallach and Doug Ostler, and set out to prove the "industry cloud" thesis.

The original company was incorporated as Verticals onDemand, Inc. The first product, Veeva CRM, launched in 2008. It ran on Salesforce's infrastructure, which gave Veeva a fast path to cloud delivery without having to build the underlying platform. This was a smart pragmatic choice that later became a constraint - but more on that later.

What happened over the next 15 years is one of the more instructive stories in enterprise software. Veeva moved progressively upstream into harder, more regulated, more technically complex parts of the life sciences workflow. The first product managed sales reps calling on doctors. The second managed the documents that governed clinical trials. The third managed regulatory submissions to the FDA. By 2024, Veeva had software running inside clinical operations, regulatory affairs, pharmacovigilance, quality management, laboratory information management, and commercial data analytics. Each product required deep domain knowledge to build, years to earn regulatory trust, and extensive customer relationships to sell.

The company went public in 2013. In 2021, it converted from a standard Delaware corporation to a public benefit corporation - a legal structure where Gassner retains significant control and the company is formally obligated to balance customer, employee, and societal interests alongside shareholder returns. This unusual governance structure reflects Gassner's stated belief that short-term financial pressure can destroy long-term product quality.

The Core Value Proposition

The problem Veeva solves is not abstract. Running a drug development program means managing hundreds of thousands of documents across dozens of systems, with every step subject to regulatory audit. A clinical trial involves eTMF documents, CTMS records, EDC data, RTSM logistics, safety reports - all of which must be linked, traceable, and inspection-ready. Before Veeva, most of this ran on a patchwork of paper, legacy on-premise systems, and generic document management tools that were neither designed for life sciences nor validated to regulatory standards.

Veeva's value proposition is threefold: compliance confidence (the software is built to FDA and ICH standards, which reduces validation burden for customers), operational efficiency (a single platform replaces multiple disconnected systems), and data integration (when clinical, regulatory, and safety systems share a common architecture, the data flows between them without manual intervention).

How the Product Actually Works

A drug development program at a large pharma company might run 10 parallel clinical trials in 20 countries simultaneously. Here is what Veeva does inside that program:

Vault eTMF stores the Trial Master File - the master repository of all documents that the FDA would inspect if it wanted to audit the trial. Everything from investigator agreements to protocol amendments to adverse event reports has to live here, version-controlled, timestamped, and traceable. Before Veeva, this was often a room full of filing cabinets or a shared drive folder. The eTMF must be inspection-ready at any moment; failure means regulatory jeopardy.

Vault CTMS (Clinical Trial Management System) manages the operational logistics - site activation, enrollment tracking, monitoring visit schedules, and performance metrics across those 20 countries.

Vault EDC (Electronic Data Capture) is where clinical investigators at hospital sites enter patient data directly. This is the system of record for the actual trial results.

Vault RTSM (Randomization and Trial Supply Management) handles drug supply logistics - ensuring the right doses get to the right sites in the right quantities, without breaking blind.

Vault RIM (Regulatory Information Management) manages the regulatory relationship with health authorities globally. Every submission to every country's health authority - FDA, EMA, PMDA in Japan, 100+ other agencies - is tracked, planned, and prepared here.

Vault Safety manages pharmacovigilance - the adverse event reports that must be submitted to regulators when a drug causes a serious unexpected side effect. The timelines are strict (15 days in many jurisdictions) and the volume is enormous for a marketed drug.

Vault QMS manages the quality management system for manufacturing - the deviation reports, corrective actions, training records, and change controls that regulated manufacturing requires.

On the commercial side, Vault CRM manages the 100,000+ pharmaceutical sales representatives who call on physicians, tracking calls, samples, and interactions - with restrictions on data sharing that no generic CRM would know to enforce.

The genius of the architecture is that these products share a common data layer (the Vault Platform), so when a drug moves from clinical trial to regulatory submission to approved commercial launch, the documents and data do not need to be manually migrated between systems. They are already connected.

"We're building an industry cloud...not just software that happens to be used in pharma. The platform is designed from the ground up for the specific needs of regulated life sciences businesses." - Peter Gassner

Section 2: Business Segments

Veeva reports two primary business segments: Commercial Solutions and R&D Solutions. The revenue from each is approximately equal in subscription terms, with R&D growing faster and now slightly larger. Underlying both is a cross-cutting professional services organization. Subscription revenue (~84% of total) and professional services (~16%) span both segments.

2.1 Commercial Solutions

Commercial Solutions is the older of the two segments. It encompasses the software and data products that a pharmaceutical company uses after a drug has been approved - to market it, sell it, and understand who is using it.

Vault CRM

The CRM product is the origin of the company and still the highest-profile product. Pharmaceutical sales representatives (or medical science liaisons, or medical affairs professionals) use it to plan and document their interactions with healthcare providers. A sales rep calling on a cardiologist logs the visit, samples distributed, talking points covered, and any feedback from the physician. This data is fed into targeting models, compliance systems, and incentive compensation programs.

The critical piece is that pharmaceutical CRM is not generic CRM. The federal Anti-Kickback Statute, the Sunshine Act, and country-specific transfer-of-value regulations create obligations around what gifts, samples, and interactions can be provided to physicians. Any CRM used in pharma must have these compliance rails built in. Generic CRM tools like standard Salesforce or HubSpot do not have this by default; building it requires deep regulatory knowledge that pharma IT departments do not want to develop internally.

Veeva's original CRM ran on Salesforce's underlying infrastructure - the platform relationship that began in 2007 and formally concluded in September 2025 when Veeva's exclusive contract with Salesforce expired. The new Vault CRM platform, generally available since April 2024, runs on Veeva's own Vault Platform infrastructure. This is a major architectural transition: Veeva has migrated from being a Salesforce application to being an independent platform. As of Q4 FY2026 (January 2026), approximately 140 customers are live on Vault CRM, with the end-of-support date for legacy CRM set at December 31, 2029.

Vault CRM extends beyond the legacy product. It integrates Campaign Manager (orchestrating digital and field campaigns from a single interface), Service Center (managing medical information calls and patient support), and Territory Manager (Align - managing field force deployment decisions). These add-ons are significant because they create natural upsell paths without requiring customers to integrate separate systems.

The Vault CRM migration is the single biggest product transition in Veeva's history. It is simultaneously their largest near-term execution risk and - if successful - a meaningful opportunity to deepen relationships with existing customers who will adopt adjacent modules during the migration process.

Data Cloud

The Data Cloud segment is Veeva's intelligence and analytics business. It has four main products, each addressing a different information need:

Veeva OpenData provides healthcare provider (HCP) and healthcare organization (HCO) reference data - essentially the master directory of physicians, hospitals, and affiliations that pharmaceutical companies use to target their commercial activities. OpenData covers more than 65 countries, with plans toward 100+. The data quality and coverage matters enormously because inaccurate HCP data means sales calls go to the wrong addresses, regulatory transfer-of-value reporting is wrong, and CRM workflows break down. OpenData competes directly with IQVIA's OneKey database, which has historically dominated this space.

Veeva Link delivers real-time intelligence on key opinion leaders and scientific experts - tracking which physicians are publishing on which topics, presenting at which conferences, and influencing which clinical guidelines. Medical affairs teams use Link to identify the most influential voices in a therapeutic area and tailor scientific engagement accordingly.

Veeva Compass is a suite of U.S. longitudinal data products - patient-level, prescriber-level, and sales-level. This is commercial analytics infrastructure. A pharma company uses Compass to understand which patients are being prescribed their drug, how their drug compares against competitors, and which physicians are switching patients between therapies. Compass competes with IQVIA's MIDAS/NPA data and Symphony Health, both of which have deep historical databases and long-standing customer relationships.

Crossix is the newest and fastest-growing piece of the Data Cloud. Crossix, acquired by Veeva in 2019, is a healthcare data analytics platform that enables pharma companies to measure the effectiveness of direct-to-consumer advertising. When a pharma company runs a television ad or a digital campaign for a drug, Crossix can connect that ad exposure to actual prescription data - showing which patients who saw the ad actually went to their doctor and asked about the medication. This closed-loop measurement is a relatively new capability in pharma marketing and is growing rapidly as companies shift more spend to digital channels. In Q1 FY2026, Crossix was growing over 30% year-over-year, making it the fastest-growing major business in the company.

The Data Cloud is significant because it creates data network effects. The more companies using Veeva's data products alongside its CRM, the more valuable the integrated intelligence becomes. A sales rep in Vault CRM who can see Compass prescribing data and Crossix campaign signals in the same interface is more effective than a rep switching between three separate tools.

Commercial Segment Competitive Position

Commercial Solutions faces its most significant competitive threat in years. Salesforce - Veeva's former platform provider - has launched Salesforce Life Sciences Cloud and had signed more than 40 life sciences customers by December 2025, including one of the top-three global pharmaceutical companies. IQVIA's OCE platform remains an alternative, with IQVIA having partnered with Salesforce to accelerate their offering.

However, the segment's competitive position is more nuanced than the headline customer count suggests. CRM is approximately 20% of Veeva's total revenue today, down from 25% two years ago - not because CRM revenue is shrinking but because other segments are growing faster. Management expects CRM to represent roughly 10% of revenue by 2030, as the overall business doubles in size. The Data Cloud, and particularly Crossix, are growing faster than CRM and face less direct competitive threat from Salesforce.

Revenue contribution: Commercial Solutions represents approximately 45% of total subscription revenue.

2.2 R&D Solutions

R&D Solutions is the segment covering the software used during drug development - from the first patient enrolled in a clinical trial through regulatory approval. This segment is now slightly larger than Commercial by subscription revenue and is growing faster. It encompasses four product areas: Clinical, Regulatory, Safety, and Quality.

Clinical

The Clinical product suite is Veeva's most complete offering in R&D. It addresses every step of running a clinical trial at the operational and document management level:

Vault eTMF is the anchor product - the earliest R&D product Veeva built after moving into development cloud. Managing the Trial Master File is a regulatory requirement, and eTMF is now deeply embedded in the workflows of every large pharmaceutical company. It was Veeva's first product to achieve full top-20 pharma penetration, making it both a template for product expansion and a demonstration of how deeply Veeva can entrench itself once it has the leading product in a category.

Vault EDC (Electronic Data Capture) is the system where investigators enter clinical trial data. This is the most competitive segment of Veeva's R&D portfolio because Medidata (now owned by Dassault Systèmes) has historically dominated the EDC market. Veeva has made significant inroads - it won its ninth top-20 pharma customer for EDC in Q4 FY2025 - but this is still an area of active competitive contest. In Q3 FY2026, management acknowledged "discrete competitive losses in EDC," a rare admission that the market is not uniformly favorable.

Vault CDMS (Clinical Data Management System) and Vault CDB (Clinical Database) work alongside EDC to provide the data cleaning and integration layer. These products turn raw clinical data into submission-ready datasets.

Vault eCOA (Electronic Clinical Outcome Assessment) captures patient-reported outcomes - symptoms, quality of life, functional assessments - directly from patients via mobile devices or electronic diaries. This segment was previously addressed by specialized vendors; Veeva's integrated approach offers data flow without manual extraction.

Vault RTSM (Randomization and Trial Supply Management) is a more recent growth area. RTSM manages the blinding logistics of a randomized controlled trial - ensuring patients get the right treatment assignment, and ensuring the right drug supplies are at the right sites. In Q4 FY2026, a major top-20 pharma company standardized on Veeva's RTSM platform, which management described as a milestone deal. RTSM was previously dominated by specialized vendors like BioClinica and Almac.

Vault Study Start-up manages site activation - the contracts, regulatory submissions, and approvals needed before a clinical site can enroll patients. This is operationally intensive and chronically slow in the industry; Veeva aims to reduce cycle times through workflow automation.

Vault SiteVault provides document management for investigator sites themselves - the hospitals and clinics running the trials. In FY2026, Veeva announced eSource, a new SiteVault application to eliminate paper at clinical sites and connect EHR data directly to the EDC system.

Vault Payments handles financial transactions between sponsors and clinical sites - paying sites for screen failures, completed visits, and enrolled patients.

What makes the Clinical suite hard to replicate: The suite has been validated to FDA 21 CFR Part 11, GCP, GDPR, and regulatory authority expectations across 100+ markets. This validation process is not a checkbox; it requires years of audit history and regulatory relationship-building. When a pharma company selects Veeva EDC for a Phase III trial, they are partly selecting the regulatory credibility that comes with Veeva's track record. A new entrant cannot replicate this overnight. The connected architecture - where eTMF, CTMS, EDC, and RTSM share a single data layer - also means that switching away from one product imposes migration costs across the entire suite.

Regulatory (RIM)

Vault RIM (Regulatory Information Management) manages the global regulatory lifecycle of a drug. Once a company has clinical trial results, it must compile and submit them to health authorities in every market where it wants to sell the drug. Vault RIM tracks all global submissions, manages variation applications as labels are updated, maintains registration status across 200+ markets, and prepares electronic submissions in the formats (eCTD, IDMP) required by regulators.

The regulatory function is the gatekeeper between a drug being approved and a company generating revenue. The consequences of a failed or delayed submission are enormous - billions in lost sales for every month of delay. Customers pay for reliability and compliance credibility above price.

Veeva holds dominant market share in RIM. No competitor has built a comparable global solution at this level of depth. Oracle's RIMS product was the previous incumbent; most large pharma companies have migrated to Veeva.

Safety

Vault Safety manages pharmacovigilance - the ongoing safety monitoring of approved drugs. Every serious adverse event reported anywhere in the world must be collected, assessed, and reported to regulators within strict timelines. A global drug with millions of patients may generate hundreds of thousands of case reports annually, each requiring medical assessment and regulatory submission.

The Safety segment is at an early-to-mid stage of Veeva's product maturity curve. Oracle's Argus Safety has been the incumbent system at most large pharma companies for decades. Migrating pharmacovigilance systems is one of the most complex IT projects in the industry - the data validation requirements, the regulatory commitment letters, and the sheer volume of historical case data make it a multi-year undertaking.

In multiple concalls, management has described Safety as approaching a "tipping point" - the point at which enough large pharma companies have made the migration decision that the category tips decisively toward Veeva. In Q4 FY2026, management explicitly identified Safety as a key target for AI automation: "It is about replacing that type of labor with automation, with AI software." Case intake, narrative generation, and duplicate detection are all labor-intensive tasks in pharmacovigilance that AI agents can theoretically accelerate, creating both a cost-reduction story and an upgrade cycle for Veeva's Safety platform.

Quality

Vault Quality is the newest large product area in R&D Solutions. It covers the quality management system (QMS) for pharmaceutical manufacturing - deviation management, corrective and preventive actions (CAPA), change control, training records, supplier management, and laboratory information management.

Vault QMS has over 100 customers and was released in 2016. Vault LIMS (Laboratory Information Management System) is newer and gaining momentum - in Q4 FY2026, momentum continued with both new logos and expansions at existing customers. Veeva announced LIMS Basics in early 2026, a simplified version targeting smaller manufacturers and emerging biotechs.

Quality is significant because it extends Veeva's reach beyond the front-end of drug development into manufacturing operations - a market that has historically been served by legacy on-premise systems like Sparta Systems (now part of Honeywell) and MasterControl. The same regulatory validation requirements that create switching costs in clinical and regulatory systems apply equally in quality.

R&D Segment Competitive Position

The R&D segment competes across multiple sub-markets. In clinical, the primary competitor is Medidata (Dassault Systèmes), which has the largest installed base in EDC and a strong RTSM offering. Oracle Health Sciences competes across clinical (Clinical One), safety (Argus), and regulatory. IQVIA offers clinical solutions including RAVE for data management. No single competitor matches Veeva's breadth across all four R&D product areas - clinical, regulatory, safety, and quality - on a unified platform.

The unified platform argument matters: a pharma company standardizing on Veeva's full development cloud eliminates point-to-point integrations between systems from different vendors. This reduces IT costs, improves data quality, and shortens the time it takes to close out a clinical trial for submission.

Revenue contribution: R&D Solutions represents approximately 55% of total subscription revenue, growing faster than Commercial and expected to continue expanding as Safety and Quality mature.

Segment Summary

Section 3: Products and Business Detail

The Vault Platform

Everything Veeva builds today - except legacy CRM - runs on the Vault Platform. Understanding Vault is essential to understanding why Veeva's competitive position in R&D is stronger than in commercial CRM.

Vault was Veeva's second major technical bet, built entirely from scratch beginning around 2010. Unlike the original CRM (which ran on Salesforce's Force.com infrastructure), Vault was designed specifically for regulated content management and transactional workflows in life sciences. The platform manages three types of objects simultaneously: documents (the regulated content), data records (the structured information that governs those documents), and now agents (AI processes that operate across documents and data).

The key architectural decisions that make Vault hard to replicate:

Built-in audit trails: Every document action - upload, view, edit, approve, delete - is logged immutably. This is a regulatory requirement; it cannot be bolted on later without complete architectural rework.

Electronic signatures with 21 CFR Part 11 compliance: The FDA requires electronic signatures to meet specific authentication and audit standards. Vault's signature infrastructure was designed to these standards.

Role-based access control at the document level: In a clinical trial, a site investigator can see the protocol but not the randomization codes; a sponsor monitor can see the trial master file but not the patient-level data. Vault's access control granularity matches these regulatory requirements.

Cross-application data sharing: Because all Vault applications share a common data layer, a drug record created in Vault RIM can be referenced in Vault Safety without manual data entry. This cross-application connectivity is only possible because they share the same underlying platform.

The Vault Platform now supports AI agents - software processes that can perform tasks within Vault's document and data environment with access to the full audit trail and compliance infrastructure. This is significant because AI agents built outside the Vault environment would lack the regulatory guardrails that make their outputs usable in submissions or safety reports. Veeva's bet is that life sciences companies will want AI that operates within their compliance infrastructure, not AI that operates outside it and requires manual validation of outputs.

Full Product Catalogue

Commercial Cloud

• Vault CRM: The core pharmaceutical sales force automation system - call planning, call recording, sampling, compliance enforcement, territory management
• Vault CRM Campaign Manager: Orchestrates coordinated digital and field campaigns, enabling a medical affairs professional to schedule email, virtual meeting, and in-person visit sequences
• Vault CRM Service Center: Manages medical information requests, patient support programs, and adverse event reporting at the call center level
• Veeva Align: Territory management and field force design - the tool pharma companies use to decide which reps cover which geographies and which physicians
• Medical CRM: A separate module for Medical Science Liaisons, with different compliance requirements and data visibility rules than commercial reps

Data Cloud

• Veeva OpenData: Global HCP/HCO reference data - currently 65+ countries, targeting 100+; the industry's authoritative source for physician name, specialty, address, and institutional affiliation
• Veeva Link: Key opinion leader intelligence - tracks scientific publication, conference activity, sentiment, and influence across therapeutic areas
• Veeva Compass: U.S. longitudinal prescriber data (NPA equivalent), patient data, and sales data, used for HCP targeting, patient journey analysis, and market share tracking
• Crossix: DTC measurement and healthcare audience platform - connects ad exposure to prescription outcomes for consumer and HCP digital marketing campaigns
• Veeva Pulse: Launched in FY2025, Pulse provides field analytics and benchmark data drawn from Veeva's network. The first product where Veeva's first deal was already at seven figures.

Clinical Suite

• Vault eTMF: Trial Master File management - the regulatory required document repository for clinical trials
• Vault CTMS: Clinical Trial Management System - operational tracking of site performance, enrollment, monitoring
• Vault EDC / CDMS: Electronic Data Capture for investigator data entry; integrated with Vault CDB for data management
• Vault CDB: Clinical database for data cleaning, coding, and review
• Vault eCOA: Electronic clinical outcome assessments - patient-reported outcomes, clinician ratings
• Vault RTSM: Randomization and Trial Supply Management - drug assignment and supply logistics
• Vault Study Start-up: Site feasibility, selection, and activation workflow management
• Vault SiteVault: Site-facing document management for investigator sites
• Vault eSource (announced, H2 2026 early adopter): Eliminates paper at clinical sites by connecting EHR data directly to EDC
• Vault Payments: Financial transactions between sponsors and sites - site payment reconciliation

Regulatory Suite (RIM)

• Vault Registrations: Global product registration tracking - status of product approvals across 200+ markets
• Vault Submissions: Regulatory submission planning, content preparation, and dossier management
• Vault Submissions Publishing: Formats regulatory dossiers into eCTD and other agency-required electronic formats
• Vault Archive: Long-term regulatory archive for approved submission content

Safety Suite

• Vault Safety: End-to-end adverse event case processing - intake, coding, narrative generation, causality assessment, regulatory reporting
• SafetyDocs: Manages the documents associated with safety surveillance - signal reports, REMS documents, safety data exchange agreements
• Safety Workbench: Analytics tool for signal detection and aggregate reporting

Quality Suite

• Vault QMS: Quality management system - deviation management, CAPA, change control, supplier qualification
• Vault QualityDocs: Controlled document management for SOPs, work instructions, and quality records
• Vault LIMS: Laboratory information management - sample tracking, test management, instrument integration for QC labs
• Vault LIMS Basics: Simplified LIMS for smaller manufacturers (announced early 2026)
• Vault Training: Training record management and content delivery for GxP-compliant training programs

Geographies

Veeva serves customers globally. The U.S. market is its largest - driven by the concentration of large pharma and biotech headquarters and the FDA regulatory environment. Europe is the second-largest market, governed by EMA requirements. Japan (PMDA) and the rest of Asia-Pacific represent a growing share. Veeva's OpenData product specifically expands geographically - its ongoing push from 65 to 100+ countries is partly a competitive moat-building exercise, since HCP reference data requires local data collection and maintenance in each market.

The company's geographic expansion is largely demand-pull: when a customer's clinical trial or regulatory program expands to a new geography, they bring Veeva with them. This reduces the need for a separate go-to-market investment in each new market.

Revenue Model

Subscription revenue (~84%) comes from multi-year enterprise software licenses. Typical contract structures are annual or multi-year, with auto-renewal provisions. Enterprise contracts for large pharma often span multiple products and are structured as enterprise agreements rather than individual module purchases.

Professional services (~16%) come from implementation, configuration, business consulting, and migration services. As Vault CRM migrations accelerate through 2026-2029, services revenue from CRM migration work is expected to grow. Veeva has historically restrained its services business (preferring to let third-party system integrators do implementations), but is now actively hiring in services to support the migration pipeline.

Section 4: Customers

Who Buys and Why

Veeva's 1,552 customers as of FY2026 year-end span three tiers:

Top-20 global biopharma: These are the largest pharmaceutical companies in the world - companies like Pfizer, Roche, Johnson & Johnson, Novartis, AstraZeneca, Sanofi. They are the most complex customers, running dozens of products and thousands of clinical trials simultaneously. 19 of the 20 largest global pharma companies are Veeva customers for at least one product. Many are customers across multiple product lines.

Mid-market pharma and specialty pharma: Companies running between 10 and 100 active programs. These customers are typically multi-product Veeva users but may not have standardized on the full suite.

Emerging biotech: Small companies - often with a single clinical-stage asset - that need compliant infrastructure without the IT resources to build it themselves. Veeva's Basics product line (Vault Basics, LIMS Basics, PromoMats Basics) specifically targets this segment with simplified configurations at lower price points. The Basics segment is growing as a source of new logos; these customers often expand their Veeva footprint as their pipelines grow.

The Buying Decision

For large enterprise customers, the buying decision for a major new Veeva product (say, migrating to Vault EDC or implementing Vault Safety) involves:

• The Chief Information Officer or Head of IT, who owns the platform architecture decision
• The functional head (Head of Clinical Operations, Head of Regulatory Affairs, Head of Quality)
• The procurement team, for contract structure
• Often, a major system integrator (Accenture, Cognizant, TCS) who will implement and configure the system

The sales cycle for a new major product at a top-20 customer can run 12-24 months. There are extensive evaluation periods, proof-of-concept implementations, and regulatory risk assessments. Once a vendor is selected and implementation begins, the cost of switching is enormous - this is what drives the long-term contract stability.

For emerging biotech customers selecting their first clinical system, the decision is much faster - often a single R&D leader choosing based on industry reputation, peer referrals, and vendor support. The Basics product line is specifically designed to reduce the friction of this initial purchase.

Switching Costs

Veeva's switching costs are among the highest in enterprise software. They operate at three levels:

Regulatory validation: Software used in clinical trials and regulatory submissions must be validated to regulatory standards. Validation documentation for a complex system like EDC or RIM takes months to create. Switching requires re-validating a new system - including a parallel run to demonstrate equivalent outputs.

Historical data depth: After five years of using Vault RIM, a regulatory affairs team has built a comprehensive global registration database inside Vault. Migrating that history to a competing system requires data mapping, transformation, and integrity testing. The risk of data loss or corruption in regulatory records is not acceptable.

Process and workflow integration: Veeva systems are configured to match each customer's specific workflows, submission templates, naming conventions, and cross-system integrations. These configurations represent years of institutional knowledge. A competitor's out-of-box system requires rebuilding all of that.

Network effects within the platform: A company using Vault RIM, Vault Safety, and Vault Clinical benefits from cross-system data flows that would be broken if one module were replaced with a competitor's product. The more modules a customer has on Vault, the stickier each individual module becomes.

The net result is extremely low voluntary churn. Customers who do leave (such as those who selected Salesforce Life Sciences Cloud for CRM) are making a deliberate strategic choice, not leaving because of dissatisfaction with day-to-day functionality. The CRM defections to Salesforce are notable precisely because they are exceptions, not the norm.

Customer Concentration

No single customer represents a material portion of Veeva's revenue. The top-20 pharma companies collectively represent a significant share of subscription revenue, but no individual customer approaches the concentration levels that would constitute a dependency risk. This is a function of deliberate strategy - Veeva has avoided exclusive preferred-provider arrangements that would create single-customer dependency.

Section 5: Competitive Landscape

Structure of the Competitive Field

Veeva competes in three distinct competitive arenas: commercial life sciences software, R&D/clinical software, and life sciences data. These arenas have different competitive dynamics, different incumbents, and different barriers to entry.

Commercial CRM - The Active Battleground

The commercial CRM segment is where competitive intensity is highest and where Veeva's advantage is most contested.

Salesforce Life Sciences Cloud: Salesforce has made the calculated bet that its platform advantage - brand recognition, developer ecosystem, AI infrastructure (Agentforce) - is sufficient to compete with Veeva's domain depth. The formal separation of Veeva and Salesforce occurred in September 2025. By December 2025, Salesforce had announced 40+ life sciences customers for its Life Sciences Cloud, including one of the top-three global pharmaceutical companies. This is meaningful: it is the first time a credible competitor has captured significant enterprise-scale CRM customers from Veeva's install base.

The Salesforce pitch is: broader platform, bigger AI investment, existing enterprise relationships, fewer single-vendor dependencies. The Veeva pitch is: built specifically for pharma compliance, proven functionality, no implementation complexity from building pharma-specific capabilities on a generic platform. The truth is that both pitches have merit, and the market is deciding. The key unresolved question is whether the six top-20 pharma companies still evaluating alternatives by Q3 FY2026 will ultimately select Salesforce or remain with Veeva.

IQVIA OCE (Orchestrated Customer Engagement): IQVIA's CRM product competes primarily in Europe and mid-market. IQVIA announced it would support its platform through 2029 while partnering with Salesforce to accelerate Life Sciences Cloud development. IQVIA is therefore effectively withdrawing from the CRM market as an independent competitor and routing its customers toward Salesforce. This removes one competitive threat to Veeva but strengthens Salesforce's position.

The limiting factor for both competitors: The Vault CRM migration is well advanced - 140 live customers by January 2026, with end-of-support set for December 2029. The window for competitors to capture CRM customers is 2025-2028. After that, customers on Vault CRM are locked into an integrated Vault Platform ecosystem that is much harder to displace. The race is time-bounded.

R&D Solutions - Veeva's Strongest Position

The R&D competitive landscape is more favorable to Veeva than commercial CRM.

Medidata (Dassault Systèmes): Medidata is the leading competitor in EDC, with a strong position in eCOA and RTSM. Medidata was acquired by Dassault Systèmes in 2019 for $5.8 billion. It has the deepest installed base in EDC among large pharma, and its platform approach (Medidata Rave for data, Clinical Cloud for operations) is the most credible integrated alternative to Veeva's Development Cloud. In EDC specifically, Medidata remains formidable - Veeva acknowledged "discrete competitive losses in EDC" in Q3 FY2026. However, Veeva has momentum: nine of the top-20 pharma companies now use Vault EDC. Where Medidata is strong: legacy relationships at top pharma, deep EDC product maturity. Where Veeva wins: newer architecture, broader suite (Medidata does not have equivalent RIM, Safety, or Quality products), single data layer.

Oracle Health Sciences: Oracle competes in clinical (Clinical One / InForm), safety (Argus Safety), and has regulatory products. Oracle's life sciences products run on the Oracle Health Sciences Cloud platform. Oracle's advantage is its enterprise software relationships - Oracle is already the ERP and database provider for many large pharma companies. Its disadvantage is product maturity: Argus Safety is long-in-the-tooth and Veeva is winning migrations from it. Oracle Clinical One has not achieved significant market penetration against Medidata or Veeva in EDC.

IQVIA Clinical Solutions (Rave, IMPACT): IQVIA operates Medidata Rave licenses as part of its CRO services business (IQVIA runs clinical trials as a CRO, using Medidata tools). The IQVIA-Veeva legal settlement in 2024 resolved a years-long data theft dispute and established a commercial partnership - importantly removing a legal overhang that had constrained Veeva's ability to integrate IQVIA's data into its products. The partnership enables better data interoperability between Veeva's clinical systems and IQVIA's data services.

Parexel: A major CRO that offers technology as part of its integrated clinical services. Competes with Veeva primarily in the study-by-study EDC and RTSM market via its Prism platform.

Data - IQVIA's Home Turf

IQVIA: The dominant incumbent in pharmaceutical data. IQVIA's data business (formerly IMS Health) built the global pharmaceutical prescription data franchise over 40+ years. Its MIDAS database for global sales data and NPA data for U.S. prescription tracking are deeply embedded in pharma commercial operations. Veeva's Compass product directly competes with IQVIA's U.S. data business, and OpenData competes with IQVIA's OneKey HCP database. The IQVIA advantage: history, relationships, and global data breadth. The Veeva advantage: usage rights (IQVIA historically imposed data-use restrictions that Veeva does not), better integration with CRM workflows.

Symphony Health / PRA Analytics: U.S. prescription data competitor to both IQVIA and Compass. Acquired by ICON in 2021.

Komodo Health, Definitive Healthcare: Newer data companies focusing on patient-level and healthcare market data. Growing but not at the enterprise scale needed to displace IQVIA or challenge Veeva's integrated Data Cloud strategy.

Crossix specifically: DTC measurement for pharma is a relatively new capability. The established players in digital measurement (Google, Meta, The Trade Desk) have general-purpose measurement tools; Crossix is purpose-built for pharmaceutical compliance requirements around patient privacy and HIPAA. This creates a defensible niche: generic ad tech cannot handle the sensitivity of connecting ad exposure to prescription data within HIPAA guardrails.

Quality Management - Relatively Open Field

MasterControl: The dominant QMS vendor for pharmaceutical manufacturing, with strong presence in mid-tier pharma and medical devices. Cloud-native but purpose-built for quality, without Veeva's broader platform breadth.

Honeywell Sparta Systems (TrackWise): The legacy QMS incumbent at many large pharma manufacturers. Moving to cloud has been slower than Veeva or MasterControl.

Veeva's quality business is relatively early-stage and benefits from the same unified platform argument: a pharma company with Veeva across clinical, regulatory, and safety has a strong reason to add quality to the same platform.

Barriers to Entry

The barriers to entering Veeva's market are real and high:

Regulatory validation history: Software used in FDA-regulated workflows must demonstrate a track record of validation support, documented testing, and regulatory acceptance. A new entrant starting from scratch faces years of validation work before a large pharma company will run a critical submission or clinical trial on its platform.

Domain knowledge: Building pharma-specific workflows requires experts who understand GCP, GMP, ICH guidelines, eCTD submission formats, 21 CFR Part 11 requirements, and dozens of other regulatory frameworks. This knowledge takes years to hire and develop.

Data network in Data Cloud: OpenData and Compass are built on data networks - relationships with pharmacies, hospitals, and healthcare data providers that took years to build. A competitor cannot simply buy access to equivalent data overnight.

Customer relationships: Enterprise pharma procurement cycles are long and relationship-driven. The CIO of a large pharma company values a vendor who knows the regulatory environment, has implementation experience at comparable companies, and can be held accountable when a regulatory submission is at stake.

The one barrier that is eroding somewhat is the AI layer: domain-specific AI startups can potentially build point solutions (say, an AI-powered adverse event intake tool) that compete with pieces of Veeva's Safety suite without needing to build the full platform. This is the most credible long-term disruption vector.

Section 6: Industry

What Drives Demand

Demand for Veeva's products is driven by pharmaceutical R&D spending, the global regulatory compliance burden, and the digital transformation of life sciences operations.

Pharma R&D spending: Global pharmaceutical R&D spending exceeded $250 billion annually in 2024, driven by innovation in oncology, immunology, GLP-1 obesity drugs, and gene therapy. More spending on drug development means more clinical trials, more regulatory submissions, and more commercial launches - all requiring Veeva's products. The pipeline of potential drugs is at historically high levels.

Regulatory complexity: The FDA, EMA, PMDA, and 100+ other health authorities are simultaneously increasing their data requirements and digitalizing their processes. FDA's data modernization program, the shift to eCTD 4.0, IDMP implementation in Europe, and decentralized clinical trial guidance all create new compliance requirements that existing legacy systems struggle to meet - driving migration to modern cloud platforms.

The compliance obligation is non-discretionary: A pharmaceutical company cannot choose not to do pharmacovigilance. It cannot choose not to file regulatory submissions. It cannot choose not to maintain a quality management system. These are legal obligations under FDA, EMA, and national regulations. This creates a demand base that is largely recession-resistant.

Digital transformation: The life sciences industry has been slower than financial services or retail to adopt cloud. The pandemic accelerated this shift - running clinical trials remotely, enabling decentralized trial models, and remote regulatory inspections all required modern digital infrastructure. Veeva benefited from this acceleration.

Industry Size

The addressable market Veeva operates in is large and growing:

• The broader life sciences software and data TAM is projected at $30-50 billion by 2028, with approximately 10% CAGR
• The pharma CRM software market reached $4.33 billion in 2024, projected to reach $9.85 billion by 2034
• The clinical trial software market is valued at approximately $1 billion in 2025, growing toward $3.7 billion by 2035
• The pharmaceutical QMS market was $1.59 billion in 2025, projected at $2.98 billion by 2030 at 13.3% CAGR
• Veeva's own 2030 target of $6 billion in revenue run rate implies a view of its accessible TAM exceeding $20 billion

Veeva currently addresses roughly $3.2 billion of its TAM in FY2026 revenue, suggesting significant headroom within its existing product categories before expanding into new ones.

Supply Chain Position

Veeva is a pure software and data company - it has no physical supply chain. Its products are delivered as cloud services from data centers (primarily AWS and its own infrastructure). The "supply chain" constraint for Veeva is talent: the regulatory domain experts, software engineers, and customer success managers who build and deploy its products.

Regulatory Environment

Life sciences software itself is not directly regulated by the FDA, but it must enable customers to comply with FDA regulations. Key regulatory frameworks that shape Veeva's products:

21 CFR Part 11 (FDA): Governs electronic records and electronic signatures. All Vault applications are designed to meet Part 11 requirements.

GxP compliance: Good Clinical Practice (GCP), Good Manufacturing Practice (GMP), and Good Pharmacovigilance Practice (GVP) collectively govern the use of software in clinical, manufacturing, and safety contexts.

EU CTR (EU Clinical Trials Regulation): Introduced in 2022, this regulation requires centralized clinical trial management across the EU, driving adoption of modern clinical systems.

ICH guidelines: International harmonization guidelines (ICH E6 for GCP, ICH M8 for electronic submissions) drive standardization of data formats and processes.

These frameworks create both a compliance burden (Veeva must ensure its products meet evolving standards) and a competitive advantage (incumbents who meet these standards are harder to displace than newcomers).

Cyclicality

The life sciences software market is among the least cyclical in enterprise software. The non-discretionary nature of compliance obligations means that pharma IT budgets are less sensitive to economic cycles than, say, marketing technology or HR software. In a recession, a pharma company can delay a new CRM implementation; it cannot stop filing adverse event reports.

The main cyclical exposure is in small biotech funding - a segment that is sensitive to interest rates, venture capital availability, and IPO markets. In Q1 FY2025, Veeva explicitly attributed part of its guidance cut to SMB/biotech macro headwinds. When biotech funding dries up, small companies cancel planned software implementations or defer expansions.

Headwinds

Drug pricing policy: The Inflation Reduction Act (IRA) in the U.S. introduced Medicare drug price negotiations, which reduce expected revenue for certain drug categories and could reduce pharma R&D investment in those areas. In Q1 FY2026, Gassner acknowledged increased uncertainty around tariffs and drug approval timelines, though reported "no material change to financial results or pipeline."

Pharma consolidation: Mergers between large pharma companies can temporarily reduce software spending as IT architectures are rationalized. The Merck-Prometheus, AstraZeneca-Alexion, and similar deals create integration periods where Veeva expansions can be delayed.

Section 7: Growth Triggers

All triggers sourced from Q1-Q4 FY2026 earnings calls, representing the four most recent quarters.

Crossix Expansion Across Five Product Lines Crossix is growing over 30% year-over-year with management noting continued expansion across five major applications: digital consumer measurement, HCP measurement, consumer audiences, HCP audiences, and an emerging identity resolution capability.

"Crossix is growing well...we're growing the product across five major applications." - Peter Gassner, Q1 FY2026 Concall, May 28, 2025

(Repeated as growth driver in Q2, Q3, and Q4 FY2026)

Vault CRM Live Customer Ramp - Full Enterprise Migration Management guided toward "vast majority" of top-20 decisions by end of FY2026, with ~140 customers live as of Q4 FY2026 and the migration pipeline expected to build through 2029.

"Vault CRM is going well...The product is actually better than Veeva CRM." - Peter Gassner, Q4 FY2026 Concall, March 4, 2026

(Mentioned across all four Q FY2026 concalls)

RTSM Enterprise Standardization - Top-20 Milestone Deal A major top-20 pharma company standardized on Vault RTSM in Q4 FY2026, described by management as a milestone deal for enterprise-level RTSM adoption. Management indicated this signals the beginning of the RTSM enterprise penetration cycle.

(Q4 FY2026 Concall, March 4, 2026)

CRO Channel as a "Billion-Dollar Business" Management identified the contract research organization channel as a dramatically underutilized distribution path for study-by-study deployments of EDC, RTSM, and eCOA. CROs run thousands of studies on behalf of pharma sponsors. Expanding through the CRO channel represents an incremental TAM that Veeva has not historically prioritized.

"We have a CRO channel opportunity that could be a billion-dollar business." - Peter Gassner, Q4 FY2026 Concall, March 4, 2026

AI Agents Across All Product Lines by End of 2026 Management committed to deploying AI agents across commercial, safety, quality, and clinical operations by end of calendar 2026. The most advanced deployment is in commercial content management (PromoMats/MLR), with safety case processing and clinical data operations next.

"We will deploy AI agents across commercial, safety, quality, and clinical by the end of 2026." - Peter Gassner, Q3 FY2026 Concall, November 20, 2025

Safety AI - Replacing Case Processing Labor Management specifically identified Safety case processing as a labor replacement opportunity for AI automation, with case intake, narrative generation, and duplicate detection as the first targets. Safety is approaching "tipping point" for enterprise standardization.

"It is about replacing that type of labor with automation, with AI software." - Peter Gassner, Q4 FY2026 Concall, March 4, 2026

eSource - New Clinical Site Application (H2 2026 Early Adopter) Veeva announced eSource, a new SiteVault application that eliminates paper at clinical sites by connecting EHR data directly to the EDC system. Early adopter availability planned for second half of 2026. This addresses one of the most persistent inefficiencies in clinical trial data collection.

(Q4 FY2026 Concall, March 4, 2026)

Horizontal Applications - First Customers Expected Gassner mentioned Veeva's ambition to expand the Vault platform into adjacent regulated industries beyond life sciences (chemicals, cosmetics, animal health). In Q1 FY2026, he expected the first horizontal customers by year-end 2025.

(Q1 FY2026 Concall, May 28, 2025)

IQVIA Partnership Unlocking Commercial Data Integrations The settlement of the IQVIA lawsuit (announced Q2 FY2025) established a commercial partnership that removes prior restrictions on integrating IQVIA data into Veeva's products. This was expected to enable new commercial content and data integration capabilities, with benefits being realized in FY2026 and beyond.

(Q2 FY2026 Concall, August 27, 2025)

Ostro Acquisition - Brand Engagement Platform (~$100M) Acquired March 10, 2026, Ostro adds AI-driven, MLR-approved conversational engagement and analytics to Veeva's commercial suite. This fills a gap in patient-facing digital engagement that Vault CRM's sales-rep focus does not address.

(Post-Q4 FY2026, disclosed March 2026)

Section 8: Key Risks

1. Salesforce CRM Defections - Concentrated Near-Term Risk

Mechanism: Salesforce Life Sciences Cloud is an actively resourced competitor backed by a much larger company with an existing enterprise footprint at every large pharma customer. If the remaining six top-20 pharma companies evaluating alternatives select Salesforce, and if Salesforce successfully signs additional mid-market customers, the CRM migration to Vault CRM could result in Veeva holding fewer than 14 of the top-20 customers - the bottom end of management's own guidance range.

How it plays out: CRM is currently 20% of revenue. If Salesforce captures 30-40% of the migrating customer base (rather than the 14/20 top-pharma retention management targets), total CRM revenue stabilizes below expectations. The mitigant is that CRM is declining as a share of total revenue and Veeva's other segments are growing faster. But sentiment damage from high-profile customer losses - especially if they include additional top-3 pharma companies - could affect the broader Veeva competitive narrative.

Probability/Magnitude: High probability of continued competitive losses (the structure of the contest is real); moderate revenue impact given CRM's declining weight.

Management acknowledged in Q3 FY2026: "CRM is about 20% of total revenue today, down from about 25% two years ago." This framing is partly defensive - but the math is real.

2. Pharma R&D Budget Pressure - IRA and Drug Pricing Policy

Mechanism: The Inflation Reduction Act enables Medicare to negotiate drug prices for certain therapies. Industry analysis suggests this reduces the expected return on certain R&D investments, which could cause pharma companies to reduce spending on clinical programs in price-sensitive therapeutic areas. Reduced R&D spending means fewer clinical trials, fewer regulatory submissions, and lower demand for Veeva's R&D cloud.

How it plays out: The impact is selective - primarily in small-molecule drugs in certain therapeutic areas. Biologics and gene therapies are partially protected by the IRA's current structure. If IRA implementation broadens or if equivalent pricing pressures emerge in Europe, the R&D spending tailwind that Veeva relies on could moderate.

Management commentary (Q1 FY2026): Management acknowledged "increased uncertainty around tariffs, drug approvals, and biotech funding" but reported "no material change to our financial results or pipeline at this time." This is a watch-it-rather-than-panic-about-it risk currently.

3. Vault CRM Migration Execution Risk

Mechanism: Migrating 1,500+ CRM customers from legacy Veeva CRM (Salesforce-based) to Vault CRM (Veeva's own platform) is among the largest coordinated IT migration programs in the life sciences industry. Each customer migration involves data migration, system reconfiguration, user training, and regulatory validation of the new system. If migrations take longer than expected, require more services resources than anticipated, or encounter data quality issues, this creates near-term revenue drag (delayed go-lives mean delayed upsell conversations) and reputation risk.

The end-of-support date has already been accelerated from September 2030 to December 2029 - which is management signaling confidence, but also compresses the timeline for customers who have not yet started their migration.

Probability/Magnitude: Medium probability; manageable magnitude if Veeva continues hiring services capacity. The main risk is that a high-profile migration goes badly and creates negative reference accounts.

4. AI Point Solutions Disrupting Specific Products

Mechanism: AI startups with no regulatory baggage can build point solutions - say, an AI adverse event intake tool or an AI regulatory submission writer - that compete with specific capabilities inside Veeva's Safety or RIM products. These tools might win in certain accounts even if they lack Veeva's integration or compliance depth, particularly at smaller companies that don't require full audit trail infrastructure.

How it plays out: AI startups win deals at emerging biotech companies with lower compliance sophistication. This doesn't immediately threaten top-20 pharma accounts but could erode the Basics segment and slow new logo growth.

Veeva's counter-argument: Gassner's position is that life sciences companies need AI that operates within their compliance infrastructure - not AI that produces outputs requiring manual validation. The bet is that Veeva's AI agents (operating inside Vault with full audit trails) will be preferred over external AI tools that operate outside the system of record.

"AI is not going to replace things like Windows, iOS, Excel, or core systems of record like SAP, Workday, or Veeva Systems. These core systems are essential." - Peter Gassner, Q4 FY2026 Concall, March 4, 2026

Probability/Magnitude: Low probability for large pharma in the near term; medium probability for small biotech segment over 3-5 years.

5. Small Biotech Funding Environment

Mechanism: Small biotechs represent a meaningful portion of Veeva's new logo growth. When VC funding dries up, small companies stop starting clinical programs, defer software implementations, or go bankrupt - all of which affects Veeva's pipeline. In Q1 FY2025, approximately 50% of the R&D guidance cut was attributed to SMB macro headwinds.

Probability/Magnitude: Moderate probability in a higher-rate environment; relatively contained magnitude given that large pharma anchors the revenue base.

6. EDC Competitive Pressure - Acknowledged

Veeva management acknowledged "discrete competitive losses in EDC" in Q3 FY2026. Medidata remains a formidable competitor in this segment with a large installed base and strong ROI reputation. If Veeva loses momentum in EDC - the most contested piece of its development cloud - this could slow the R&D segment growth rate.

Mechanism: EDC decisions often drive follow-on decisions about CTMS, eCOA, and RTSM (since they share data). Losing an EDC deal can mean losing the adjacent products too.

7. Geographic and Foreign Exchange Risk

Veeva reports in U.S. dollars, but a significant portion of revenue is generated in Europe, Japan, and other international markets. Foreign exchange was a headwind of approximately $10 million in FY2025 guidance. This is a mechanical FX risk, not a competitive one.

Section 9: Walk the Talk

Management credibility across the four most recent concalls shows a consistent and notable pattern: Veeva systematically beats its financial guidance while navigating specific product-level milestones with more mixed results.

Q1 FY2026 - Strong Start, But Strategic Nuance

Going into Q1 FY2026 (call: May 28, 2025), management carried forward the ambition set at the Q4 FY2025 call: a $3 billion annual revenue run rate for calendar 2025, Vault CRM live at approximately 80 customers, and Crossix growing strongly.

The Q1 FY2026 revenue of $759 million beat guidance meaningfully. The $3 billion annual run rate goal was achieved. Gassner confirmed 46% non-GAAP operating margins - among the highest in enterprise software at Veeva's scale. These were kept promises.

On Vault CRM, Gassner guided for approximately 200 live customers by year-end 2025. He also said Veeva expected its first horizontal applications customer (outside life sciences) by year-end 2025. Both were aspirational targets on the aggressive end.

Macro caution was added: management noted "increased uncertainty around tariffs, drug approvals, and biotech funding" but explicitly said no material change had been observed. This was responsible disclosure - setting expectations without alarming the market.

Q2 FY2026 - Beat and Raise, IQVIA Resolution Benefits

The Q2 FY2026 result (call: August 27, 2025) showed continued financial delivery above guidance. Revenue of $789 million beat expectations, full-year guidance was raised by $35 million, and operating margins remained at industry-leading levels.

The IQVIA partnership's commercial benefits began materializing. Gassner described the resolution as removing restrictions that had limited Veeva's ability to integrate IQVIA's commercial data into its products. Nine of the top-20 pharma were now committed to Vault CRM. This met the target management had been building toward.

The quarter showed no evidence of the macro uncertainty from Q1 affecting results. Management's Q1 framing - "monitoring but not changing numbers" - proved accurate.

Q3 FY2026 - Financial Beat, Strategic Admission

Q3 FY2026 (call: November 20, 2025) produced another financial beat - $811 million in revenue versus $792.75 million guided. Operating margins remained strong. Full-year guidance was set at $3.14 billion.

But this call contained the most significant strategic disclosure of the FY2026 cycle: management acknowledged that 14 of the top-20 pharma companies had committed to Vault CRM, but that six were "exploring alternatives." This was a meaningful admission - it implicitly confirmed that some of the remaining top-20 accounts had moved toward Salesforce.

The market's reaction - a stock decline despite the beat - reflected this strategic concern. Management's framing was careful: CRM is declining as a share of revenue, the multi-year migration timeline means no near-term financial impact, and "customer-specific situations" rather than systemic product issues drove the decisions. This is partly true and partly management shaping a narrative around a real competitive setback.

The 200-live-customers-by-year-end target from Q1 was quietly not reiterated; the live count at year-end January 2026 came in at ~140, well below the Q1 aspiration.

Q4 FY2026 - Full-Year Delivery, Strategic Confidence

Q4 FY2026 (call: March 4, 2026) closed the fiscal year with $836 million in Q4 revenue and $3.195 billion for the full year - beating the $3.14 billion Q3 guidance by approximately $55 million. Non-GAAP operating income of $1.434 billion and margins at record levels. This was the third consecutive fiscal year of 16% revenue growth.

The $6 billion 2030 revenue run rate target (set at Q4 FY2025 call) was reaffirmed. FY2027 guidance of 13% subscription revenue growth was issued with confidence. Management introduced the CRO channel as a "billion-dollar business" opportunity - a new growth narrative that had not been explicitly articulated in prior quarters.

On Vault CRM specifically, 140 live customers with "strong execution" was the message. Management did not revisit the 200-customer target from Q1. The gap was not acknowledged; it was simply not re-discussed. This pattern - walking away from specific product-level targets when they are not met, while financial targets are consistently met - is a recurring feature.

Assessment

Veeva's management under Peter Gassner is consistently reliable on financial guidance - they have beaten subscription revenue, total revenue, and operating margin guidance in every quarter across the FY2026 cycle. The pattern is conservative financial guidance + consistent beats.

On product-specific milestones (Vault CRM live customer counts, horizontal expansion timelines), management sets aspirational targets that are not always met on the stated timeline. The strategic framing is coherent and often accurate - CRM decline being offset by broader growth, the competitive losses being framed in revenue terms rather than customer count terms - but investors relying on specific product milestone numbers would have been disappointed.

The most important credibility question going forward is whether the 2030 $6 billion target is realistic. Given the CRO channel, Safety and Quality maturation, AI agent monetization, Crossix growth, and R&D product expansion, the building blocks are present. But 2030 requires compound annual growth of approximately 11% from FY2026 levels - achievable but not a certainty.

Section 10: Scenarios

Bull Case

In the bull scenario, Vault CRM retains 14+ of the top-20 pharma companies, and the migration cycle (2026-2029) proves to be an upsell moment rather than a risk moment. Each migrating customer expands onto Campaign Manager, Service Center, and medical CRM modules during their migration - adding subscription revenue without corresponding customer acquisition cost. The six top-20 companies exploring alternatives have a poor experience with the complexity of custom-building on Salesforce with third-party system integrators, and some return to Vault CRM.

Crossix continues compounding at 20-30% annually as pharma digital marketing budgets grow and the measurement use case expands from consumer media into HCP media, social, and programmatic. The Compass data business displaces IQVIA's U.S. prescription data contracts as Veeva's CRM integration advantage becomes undeniable.

Safety hits its tipping point: three or four more top-20 pharma companies announce Oracle Argus migrations to Vault Safety over 2026-2027, creating a reference cascade. AI agents in Safety materially reduce pharmacovigilance staffing costs and drive rapid upsell to the automation tier.

The CRO channel materializes: Veeva's deployment through CROs adds thousands of study-level EDC, RTSM, and eCOA deployments annually, a business that was previously unaddressed. This alone adds hundreds of millions of incremental run-rate revenue by 2028.

In this world, Veeva's $6 billion 2030 goal is not ambitious - it is conservative.

Base Case

In the base scenario, Veeva executes broadly in line with its FY2027 guidance and builds toward the 2030 target at roughly 13-14% compound annual growth.

Vault CRM retains approximately 12-14 of the top-20 pharma companies. The six undecided accounts split between Salesforce and Vault CRM, with no high-profile additional defections beyond the one top-3 pharma already announced by Salesforce. Mid-market CRM remains predominantly Veeva, because the complexity of Salesforce implementations at smaller companies favors the Vault CRM out-of-box approach.

Crossix grows at 15-25% annually, contributing meaningfully to commercial subscription. R&D segment growth stays in the 15-19% range, driven by Safety and Quality maturation, continued EDC penetration, and RTSM enterprise wins. AI agents generate incremental revenue on a token-based model from 2027 onward, but remain immaterial to the income statement through FY2028.

Services revenue grows 10-15% as CRM migration demand offsets the long-term decline in implementation services from an increasingly self-service Basics product line.

The business in 2028 looks like a more complete R&D platform company with a stable commercial base - the CRM risk having been absorbed, the Safety and Quality flywheel turning, and AI adding option value.

Bear Case

In the bear scenario, the Salesforce competitive threat in CRM is more damaging than the base case assumes. Salesforce's Agentforce AI capabilities prove compelling to pharma IT departments, and instead of retaining 12-14 of the top-20, Veeva retains only 8-10. More critically, Salesforce wins at the mid-market too, capturing 20-30% of Veeva's ~300 mid-tier CRM customers as they reach their legacy CRM migration decision point.

The revenue impact is not catastrophic in the near term (CRM is only 20% of revenue), but the strategic signal is severe. If Salesforce can beat Veeva at CRM, the precedent for other Vault products becomes uncomfortable. IT decision makers at pharma companies begin asking: "If we're using Salesforce for CRM, should we reconsider whether we need Vault for content management?"

Simultaneously, IRA-driven pharma R&D budget reductions prove more material than management's "no material change" language suggests. A significant reduction in industry R&D spending cuts the number of new clinical programs that require Vault EDC, CTMS, and RTSM deployments.

Crossix growth moderates as pharma digital marketing budgets face scrutiny in a tighter spending environment, and IQVIA launches a competing measurement product leveraging its own first-party prescription data with better privacy compliance.

In this scenario, the 2030 $6 billion target requires a significant acceleration from the trajectory established through 2027 - achievable only if Safety and Quality fully standardize, and the CRO channel develops faster than anyone expects. The business remains profitable and growing, but the growth rate compresses toward single digits and the premium valuation attached to the current growth narrative faces pressure.

Sources

• Veeva Systems Q4 FY2026 Earnings Call Transcript - The Motley Fool
• Veeva Systems Q4 FY2026 Earnings Call - Investing.com
• Veeva Systems Q3 FY2026 Earnings Call - Investing.com
• Veeva Systems Q1 FY2026 Earnings Call - Investing.com
• Veeva Q4 FY2025 Earnings Call - The Motley Fool
• Veeva Q3 FY2025 Earnings Call - The Motley Fool
• Veeva Q2 FY2025 Earnings Call - The Motley Fool
• Veeva Systems Annual Reports - IR
• Veeva FY2026 Full Year Results Announcement
• Veeva Development Cloud Products
• Veeva Vault Platform
• Veeva AI Agents Announcement
• Veeva Expanded Partnership with Roche
• Veeva Data Cloud Architecture Announcement
• Vault LIMS Gains Momentum - Veeva
• IQVIA-Veeva Partnership and Legal Resolution - MobiHealthNews
• Veeva vs Competitors - IntuitionLabs
• Veeva Vault CRM Migration Roadmap - IntuitionLabs
• Veeva 2021-2026 Evolution - IntuitionLabs
• Peter Gassner - Wikipedia
• Veeva Systems - Wikipedia
• Medidata and Veeva eClinical Market - MarketsandMarkets
• Life Sciences Software TAM Analysis - MatrixBCG
• Clinical Trials Software Market Size - GlobeNewswire
• Veeva FY2027 Guidance Analysis - TIKR